Monteris Medical Study Links NeuroBlate Laser Therapy to Tripled Survival in Recurrent Brain Tumors

New updates have been reported about Monteris Medical.

Monteris Medical is at the center of new peer‑reviewed evidence indicating its NeuroBlate laser interstitial thermal therapy (LITT) can significantly boost the effectiveness of pembrolizumab (Keytruda) in patients with recurrent high‑grade astrocytoma, including glioblastoma. A Phase 1/Phase 2b randomized trial published in Nature Communications found that NeuroBlate used before immunotherapy was safe, well‑tolerated and associated with more than a threefold overall survival advantage versus conventional surgery or biopsy followed by the same drug.

Investigators from Washington University, the University of Florida and the University of Southern California report that thermal ablation with NeuroBlate appears to temporarily disrupt the blood‑brain barrier and activate an immune response, potentially overcoming a key limitation that has historically blunted the impact of checkpoint inhibitors in brain cancer. Monteris CEO Martin J. Emerson framed the data as strategic validation of the company’s decade‑long investment in MR‑guided, robotically controlled LITT, positioning NeuroBlate not only as a minimally invasive alternative to open neurosurgery but also as an enabling platform for next‑generation therapies such as immuno‑oncology.

For Monteris, the findings strengthen the clinical and economic case for NeuroBlate adoption in leading cancer centers, particularly for patients with few remaining treatment options. The company already markets NeuroBlate for brain tumors and drug‑resistant epilepsy in adults and children aged two and older, and prior multicenter studies have shown shorter hospital stays, low complication rates and outcomes comparable to open resection. The new survival data may support broader reimbursement, stimulate additional trials in combination regimens and reinforce Monteris’s competitive differentiation as the only LITT system with a robotic interface and prospective clinical evidence base.

Clinicians quoted in the study, including USC’s Dr. David Tran, suggest that NeuroBlate’s role could extend beyond debulking tumors to actively priming the immune system, opening a path to combination strategies that could reshape standards of care in recurrent high‑grade brain tumors. For stakeholders, the publication in a high‑impact journal provides external validation that may influence hospital purchasing decisions, research collaborations and potential strategic interest from partners focused on neuro‑oncology and immunotherapy.